Blue Marble Biomaterials Announces Intent to Offer Equity Shares to the Public
Blue Marble Biomaterials (Blue Marble) today announced its intent to offer equity shares to the public through Regulation A+, a type of equity crowdfunding regulated by the Securities and Exchange Commission. A natural biochemical pioneer, Blue Marble intends to use the capital raised through its online public offering to expand production capabilities and research and develop new natural chemicals.
Blue Marble Biomaterials produces naturally derived, drop-in replacement ingredients (biochemicals) that replace synthetic, petroleum-based chemicals (petrochemicals)—which can be found in 95% of consumer products used every day.
“When people realize that they are feeding their children products with ingredients manufactured from petroleum and ending their day by rubbing crude-oil derived products on their face, they are horrified,” said Colby Underwood, co-CEO of Blue Marble. “Consumers are increasingly concerned about the environment and what they are putting into and onto their bodies and those of their families, and those concerns are driving a demand for change. We’re giving manufacturers a way to meet that demand.”
Blue Marble is partnering with Manhattan Street Capital (MSC) to host the company’s “Test the Waters” campaign and additional activities. MSC specializes in providing businesses with the services and information to raise growth capital through a Regulation A+ offering.
For the full article, please click here.